一、质押变动的基本情况 证券代码：300347 证券简称：泰格医药 公告编码（2025）040 号 杭州泰格医药科技股份有限公司 关于持股 5%以上股东部分股份回购并解除质押的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）近日接到公司持股5%以上股东曹 晓春女士通知，获悉曹晓春女士办理其持有的部分股份回购并解除质押业务，具体内容如 下： | 曹晓春 | 51,314,174 | 5.96% | 22,600,000 | 20,000,000 | 38.98% | 2.32% | 20,000,000 | 100% | 18,746,330 | 59.87% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 叶小平 | 177,239,541 | 20.58% | - | - | - | - | - | - | 132,929,656 | 75% | | 合计 | 228,553,715 | 26.54% ...

文/华夏ESG观察联盟 在合规流程优化方面，公司财税合规组与相关业务及职能部门协同合作，系统梳理采购业务中的税务合 规要点、财务审核流程及法律风险防控措施，并据此完善合规管理机制。在授权管理方面，公司全面梳 理了内部11项关键业务环节的授权流程，与各相关部门对现状和潜在的风险进行评估并进行相应的调 整，确保批准相关活动或决策的信息可追溯，防止滥用权限和潜在的不当行为。 公司制定并执行覆盖全员的《泰格医药反贪污与反贿赂政策》。2024年，开展面向全员的反腐败培训和 面向关键部门的专项培训，并在《员工行为准则》中对商业道德与反腐败行为规范作出明确要求。与此 同时，公司强化采购环节对供应商反腐败的管理，要求新增供应商在准入阶段签订《供应商行为准则》 及《反贿赂反腐败承诺》，以保障供应商知悉公司的反贪污与反贿赂政策。 公司持续优化数据安全管理机制，由专项合规组及数据保护官（DPO）从集团层面搭建数据安全管理体 系。通过强化网络安全防护、优化数据生命周期管理、加强信息访问权限控制等手段，严格执行数据合 规要求，确保隐私信息和商业机密的有效保护。公司ISO 27001:2013信息安全管理体系认证截至目前持 续有效，三项 ...

Group 1 - The top three companies with the highest short positions as of September 19 are ZTE Corporation (00763) at 15.35%, COSCO Shipping Holdings (01919) at 14.10%, and CATL (03750) at 13.44% [1][2] - The companies with the largest absolute increase in short positions are China Education Holdings (00839) with an increase of 2.61%, Dongfang Electric (01072) with an increase of 2.06%, and Xiexin Technology (03800) also with an increase of 2.06% [1][2] - The companies with the largest absolute decrease in short positions are Hua Hong Semiconductor (01347) with a decrease of -2.52%, Chifeng Jilong Gold Mining (06693) with a decrease of -1.77%, and Laikai Pharmaceutical-B (02105) with a decrease of -1.72% [1][2] Group 2 - The latest short position data shows that ZTE Corporation maintained 116 million shares, COSCO Shipping Holdings had 406 million shares, and CATL had 20.95 million shares [2] - The companies with the largest increase in short positions include China Education Holdings, which rose from 3.73% to 6.33%, and Dongfang Electric, which rose from 7.34% to 9.40% [2] - The companies with the largest decrease in short positions include Hua Hong Semiconductor, which fell from 9.00% to 6.48%, and Chifeng Jilong Gold Mining, which fell from 3.30% to 1.53% [2][3]

Core Viewpoint - Pharmaceutical stocks are under pressure following the announcement of new tariffs on imported pharmaceutical products by U.S. President Trump, which could significantly impact the industry [1] Group 1: Stock Performance - Companies such as 科济药业-B (02171) saw a decline of 5.11%, trading at 18.37 HKD [1] - 康宁杰瑞制药-B (09966) dropped by 3.48%, with a trading price of 12.22 HKD [1] - 维亚生物 (01873) fell by 3.52%, now priced at 2.47 HKD [1] - 泰格医药 (300347) (03347) decreased by 3.1%, trading at 45.6 HKD [1] Group 2: Tariff Announcement - Starting October 1, the U.S. will impose a 100% tariff on all brands and patented pharmaceutical products [1] - Trump indicated that these tariffs will not apply to companies that build factories in the U.S., defining such facilities as "under construction" [1] Group 3: Policy Context - Trump's administration has focused on "lowering drug prices" and "supply chain repatriation" as key themes in its policies affecting the pharmaceutical industry this year [1]

Group 1 - Pharmaceutical stocks are under pressure, with notable declines: 科济药业-B down 5.11% to 18.37 HKD, 康宁杰瑞制药-B down 3.48% to 12.22 HKD, 维亚生物 down 3.52% to 2.47 HKD, and 泰格医药 down 3.1% to 45.6 HKD [1] - On September 25, President Trump announced a new round of high tariffs on various imported products, including a 100% tariff on all brands and patented pharmaceutical products starting October 1 [1] - The tariffs will not apply to companies that build factories in the U.S., defined by Trump as "under construction" [1] Group 2 - Trump's policies this year have focused on the pharmaceutical industry, with key themes being "lower drug prices" and "supply chain repatriation" [1]

中期報告 INTERIM REPORT 目錄 | 公司資料 | | 2 | | --- | --- | --- | | 財務摘要 | | 4 | | 管理層討論與分析 | | 5 | | 企業管治及其他資料 | 6 | 4 | | 合併資產負債表 | 7 | 0 | | 合併利潤表 | 7 | 2 | | 合併現金流量表 | 7 | 4 | | 合併所有者權益變動表 | 7 | 6 | | 財務報表附註 | 7 | 8 | | 釋義 | 1 1 | 8 | 翁美儀女士 授權代表 葉小平博士 翁美儀女士 公司資料 董事會 執行董事 葉小平博士 （董事長） 曹曉春女士 吳灝先生 聞增玉先生 獨立非執行董事 廖啟宇先生 袁華剛先生 劉毓文女士 公司秘書 監事 張炳輝先生 （主席） 陳智敏女士 樓文卿女士 戰略發展委員會 葉小平博士 （主席） 吳灝先生 袁華剛先生 劉毓文女士 審計委員會 廖啟宇先生 （主席） 袁華剛先生 劉毓文女士 薪酬與評核委員會 袁華剛先生 （主席） 廖啟宇先生 曹曉春女士 提名委員會 劉毓文女士 （主席） 廖啟宇先生 聞增玉先生 核數師 立信會計師事務所（特殊普通合夥） 中國上海市 南京東路6 ...

Group 1 - The core viewpoint of the news is that Tiger Med has seen a significant increase in its stock price, rising by 5.17% to reach 60.79 CNY per share, with a total market capitalization of 52.342 billion CNY [1] - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering a range of services from Phase I to IV clinical trials [1] - The company's main revenue sources include clinical trial-related services and laboratory services, accounting for 52.60%, clinical trial technical services at 45.21%, and other supplementary services at 2.19% [1] Group 2 - Morgan Fund has a significant holding in Tiger Med, with the Morgan CSI Innovative Drug Industry ETF (560900) reducing its stake by 3,000 shares in the second quarter, now holding 18,100 shares, which represents 2.76% of the fund's net value [2] - The Morgan CSI Innovative Drug Industry ETF has a total scale of 34.9084 million CNY and has achieved a year-to-date return of 36.18%, ranking 1270 out of 4220 in its category [2] - The fund manager, Mao Shichao, has been in charge for 5 years and 140 days, with the best fund return during his tenure being 56.22% and the worst being -24.75% [3]

Group 1 - The stock price of Tigermed (300347)(03347) increased by over 6%, reaching 47.98 HKD with a trading volume of 62.54 million HKD [1] - Citic Securities reported that Tigermed is enhancing its global presence and service capabilities, with significant teams in regions such as the US, Europe, Middle East, Africa, Japan, and South Korea [1] - In the first half of the year, the company's domestic main business revenue was 1.638 billion CNY, a decrease of 10.1% year-on-year, while overseas main business revenue was 1.541 billion CNY, an increase of 4.6% year-on-year [1] Group 2 - The growth in overseas revenue is attributed to the company's continued global expansion and service capabilities, accelerating its internationalization process [1] - The overseas clinical business maintained rapid growth, with an increase in revenue from clinical trial technical services [1] - The company announced the acquisition of Japanese CRO Micron in July 2025, which will enhance its local team in Japan and expand its client coverage in the Asia-Pacific region [1] Group 3 - The overseas clinical operations business showed a rapid growth trend, particularly in North America, with significant new order contributions expected in the second half of the year [2] - The clinical registration business experienced a notable recovery, with revenue growth exceeding 20% year-on-year, driven by increased demand for IND-related services both domestically and internationally [2] - The company established a data governance team in the first half of the year, launching multiple digital products to enhance digital management and integrating AI technology to improve digital capabilities [2]

Core Viewpoint - Tiger Med (03347) has seen a stock price increase of over 6%, attributed to its ongoing global expansion and service capabilities, particularly in overseas markets [1][2] Group 1: Financial Performance - In the first half of the year, the company's domestic main business revenue was 1.638 billion yuan, a year-on-year decrease of 10.1% [1] - The overseas main business revenue reached 1.541 billion yuan, showing a year-on-year growth of 4.6%, driven by the deepening of global layout and service capabilities [1] - The clinical registration business experienced a significant recovery, with revenue growth exceeding 20% year-on-year, benefiting from increased demand both domestically and internationally [2] Group 2: Strategic Initiatives - The company announced the acquisition of Japanese CRO Micron in July 2025, which will enhance its local team and expand client coverage in Japan and the Asia-Pacific region [1] - The establishment of a data governance team and the launch of multiple digital products have been initiated to improve digital management and integrate AI technology for enhanced operational efficiency [2] Group 3: Market Outlook - The overseas clinical operations business is showing a rapid growth trend, particularly in North America, with expectations of significant new order contributions in the second half of the year [2]

香港联交所最新资料显示，9月17日，易方达基金减持泰格医药(03347)87.69万股，每股作价46.5701港 元，总金额约为4083.73万港元。减持后最新持股数目为1082.74万股，持股比例为8.79%。 ...